Sagility India: Motilal Oswal sets ₹58 target in 2026

Brokerages turn constructive on Sagility India

Sagility India has come back into focus after multiple brokerages issued positive calls and higher target prices. Motilal Oswal Financial Services (MOFSL) reiterated a Buy rating with a target price of ₹58 in a research report dated March 27, 2026. Separate coverage initiation by Nomura and updates from ICICI Securities added to the positive tone around the stock. The combined commentary centres on Sagility’s positioning in US healthcare-focused business process management and the role of technology, including artificial intelligence, in improving delivery models. The stock also saw sharp price moves around these reports and around its quarterly results.

What Motilal Oswal said in its March 2026 note

In its March 27, 2026 report, MOFSL said it expects Sagility to deliver low- to mid-teens growth, supported by higher volumes from top clients, new client additions, cross-selling, and synergy benefits from the Broadpath acquisition. The brokerage expects this to translate into revenue/EBIT/PAT CAGR of 20%/28%/23% over FY25–FY28. Based on this view, MOFSL reiterated Buy and maintained a target price of ₹58, citing a valuation of 20x FY28E EPS. The report framed the investment case around execution, scaling within existing accounts, and synergy-led efficiency.

A second Motilal Oswal view: ₹66 target after Q3FY26

MOFSL also issued another note dated January 28, 2026, reiterating Buy with a higher target price of ₹66, based on 22x FY28E EPS. In that note, the brokerage said Sagility’s 3QFY26 revenue rose 29.1% YoY in constant currency, above its earlier estimate of 21% YoY. The brokerage projected revenue/EBIT/PAT CAGR of 21%/30%/24% over FY25–FY28, driven by new logo additions, cross-selling, and synergy from Broadpath. The same coverage highlighted that revenue conversion from deal wins and cross-sell opportunities could have been better, even as the broader momentum remained healthy.

Nomura initiates coverage; stock rallies mid-week

A separate development was Nomura initiating coverage on Sagility with a Buy recommendation and a ₹55 target price. On the back of that trigger, Sagility shares rallied sharply during a Wednesday session, rising 8% to an intraday high of ₹40.29. At the time of writing in the cited update, the stock was still trading about 7% higher. The report also noted that the stock had touched its 52-week low in the prior week, though the exact low value was not provided.

ICICI Securities raises target to ₹76

Following the company’s performance in the December 2025 quarter, ICICI Securities maintained a Buy rating and revised its target price to ₹76. The coverage cited in the provided text described this as implying up to 55% upside potential (as per that report’s framing). Alongside ICICI Securities, the broader set of analyst notes in the provided material also referenced a target of ₹70 in the context of regulatory pressures on US payers and the expectation that those pressures can accelerate outsourcing and platform adoption.

Market size and operating niche: US healthcare BPM

Sagility is described as providing business process management services to the American healthcare industry, often referred to as healthcare BPO. The cited commentary pegged the US healthcare market at about $1 trillion, with an estimate that it could cross $1.1 trillion by 2028. That expanding market context is presented as the long runway in which outsourcing vendors operate, particularly as payers and providers look to manage costs and administrative complexity.

Technology shift: AI and outcome-based contracts

The provided commentary also highlighted technology, especially artificial intelligence, as a major driver of transformation in healthcare operations. In the same narrative, Sagility was described as being well placed to benefit from that shift. One operational change mentioned was a move away from a traditional per-employee billing model to an emphasis on outcome-based contracts. The implication in the cited material is that this shift can align delivery to measurable outcomes, though the text does not quantify the financial impact of this model change.

Acquisition-led capability building

Sagility’s growth strategy in the provided material includes targeted acquisitions to expand capability sets. Examples mentioned include acquiring Devlin Consulting for payment integrity, Bergii for AI automation, and Broadpath Healthcare Solutions for entry into the payer mid-market. The MOFSL notes repeatedly referenced synergy from Broadpath as a contributor to multi-year growth expectations. These acquisitions were presented as part of a planned approach to broaden offerings and deepen relevance for US healthcare clients.

Quarterly performance and guidance highlights

The material cites a strong Q3FY26 performance, with 29.1% YoY constant-currency revenue growth. It also reported adjusted PAT of ₹3.2 billion, compared with a market expectation of ₹2.8 billion. Management raised FY26 constant-currency revenue growth guidance to 22.5%, while maintaining adjusted EBITDA margin guidance at 25%. For Q4FY26, Sagility indicated it expects revenue, EBIT, and adjusted PAT to grow 37.6% to 62.0% YoY. One broker note also cited Q3 EBITDA margin at 25.9%, while modelling margins in the 24%–25% range for FY26–FY28 due to pricing and cost pressures faced by US health insurers.

Stock moves around results and brokerage notes

Despite strong quarterly numbers, the stock saw a post-results dip in late January. The provided text said the share fell over 5% to an intraday low of ₹49.1 on January 29, 2026. Another update said the stock was trading around ₹49.93, roughly 14% below its 52-week high of ₹57.89. Separately, around 1:00 PM in one trading session, the stock was quoted at ₹49.92, down 3.5%, compared with the previous close of ₹51.70 on the NSE.

Key numbers at a glance

Why the story matters for investors

The cluster of brokerage updates shows Sagility being evaluated on two linked tracks: near-term delivery against upgraded guidance and longer-term positioning in US healthcare outsourcing. The multi-year CAGR expectations cited by MOFSL depend on sustained execution in new client additions, cross-selling, and realization of acquisition synergies, particularly from Broadpath. At the same time, multiple notes referenced pricing and cost pressures among US health insurers, which are shaping margin expectations and limiting near-term expansion assumptions. The move toward outcome-based contracts and the emphasis on AI-led transformation were presented as strategic responses to these pressures.

What to watch next

From the information provided, near-term attention is likely to remain on Q4FY26 delivery against the stated 37.6%–62.0% YoY growth expectation for revenue, EBIT and adjusted PAT. Investors will also track whether the upgraded FY26 constant-currency revenue guidance of 22.5% is achieved while maintaining the 25% adjusted EBITDA margin guidance. On the brokerage side, the spread of targets in the provided material spans ₹55 to ₹76, with MOFSL’s targets varying by report date (₹58 in March and ₹66 in January), reflecting changes in assumptions and valuation multiples.

Conclusion

Sagility India has seen renewed attention after Buy calls from Motilal Oswal, coverage initiation by Nomura, and a higher target by ICICI Securities. The factual backdrop includes strong Q3FY26 constant-currency growth, upgraded FY26 guidance, and continued focus on acquisition synergies and technology-led delivery models. The next key checkpoints, based on the provided information, are the company’s execution in Q4FY26 and follow-through on its FY26 revenue and margin guidance.